Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Pharmacokinetic evaluation of pemetrexed

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Glucagon Receptor Antagonist LY2409021 has No Effect on Postprandial Glucose in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Vitamin D supplementation improves fasting insulin levels and HDL cholesterol in infertile men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Glucagon Clearance is Preserved in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Albiglutide is a once-weekly, glucagon-like peptide-1 receptor agonist approved during 2014 in both the US and Europe for the treatment of adults with type 2 diabetes. The recommended dose is 30 mg with the possibility of uptitration to 50 mg based on individual glycemic response.

AREAS COVERED: Here, we outline the pharmacokinetics, pharmacodynamics and clinical efficacy data originating from the Phase I - III studies carried out to obtain market authorization for albiglutide.

EXPERT OPINION: The eight Phase III clinical trials have provided evidence that albiglutide in monotherapy and as an add-on to different background therapies confers placebo-corrected reductions in glycemia with changes in glycated hemoglobin of -0.8 to -1.0%. Albiglutide did not cause significant weight loss compared to placebo, but the adverse events profile was favorable with gastrointestinal adverse events occurring only slightly more with albiglutide than placebo. There is no clinical evidence of an effect of albiglutide on major cardiovascular outcomes.

OriginalsprogEngelsk
TidsskriftExpert Opinion on Drug Metabolism & Toxicology
Vol/bind11
Udgave nummer9
Sider (fra-til)1493-503
Antal sider11
ISSN1742-5255
DOI
StatusUdgivet - 2015

ID: 46021531